Brought to you by:
ATEV shows promise in high-risk patients on hemodialysis
Results from the CLN-PRO-V007 pivotal phase 3 clinical trial of the acellular tissue engineered vessel (ATEV; Humacyte) in arteriovenous access for patients at high risk of autologous arteriovenous fistula (AVF) maturation failure with end-stage renal disease were presented at the…
IN.PACT AV DCB sustained ‘superior’ effectiveness in subgroups with high reintervention rates out to two years
Several subgroups of patients treated with the IN.PACT AV drug-coated balloon (DCB) for arteriovenous fistulas (AVFs) demonstrated a “statistically significant” higher rate of target lesion primary patency (TLPP) compared to those who underwent standard percutaneous transluminal angioplasty (PTA) through 24…
Pearls of wisdom for interns
It’s June and, in less than a month, a swarm of new faces, and freshly minted MDs and DOs will descend upon most academic teaching hospitals. Many will just be getting used to being called “Dr.” They may look around…
Risk of ‘feared’ ischemic steal syndrome comparable for tapered and non-tapered AVGs
In a recent systematic review and meta-analysis, Venkata Sai Jasty, from the University of Arizona College of Medicine in Tuscon, Arizona, and colleagues found that the risk of ischemic steal syndrome, “one of the most feared complications in vascular access,”…